NASDAQ:AXLA Axcella Health - AXLA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Axcella Health Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.42 0.00 (-0.33%) (As of 03/22/2023 10:40 AM ET) Add Compare Share Share Today's Range$0.42▼$0.4350-Day Range$0.36▼$0.7752-Week Range$0.16▼$2.89Volume15,768 shsAverage Volume1.22 million shsMarket Capitalization$30.70 millionP/E RatioN/ADividend YieldN/APrice Target$5.25 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Axcella Health MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside1,157.8% Upside$5.25 Price TargetShort InterestBearish7.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 3 Articles This WeekInsider TradingSelling Shares$394 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.39) to ($0.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector487th out of 983 stocksBiological Products, Except Diagnostic Industry85th out of 163 stocks 3.3 Analyst's Opinion Consensus RatingAxcella Health has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.25, Axcella Health has a forecasted upside of 1,157.8% from its current price of $0.42.Amount of Analyst CoverageAxcella Health has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.01% of the float of Axcella Health has been sold short.Short Interest Ratio / Days to CoverAxcella Health has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Axcella Health has recently increased by 48.80%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAxcella Health does not currently pay a dividend.Dividend GrowthAxcella Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AXLA. Previous Next 1.8 News and Social Media Coverage News SentimentAxcella Health has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Axcella Health this week, compared to 1 article on an average week.Search InterestOnly 10 people have searched for AXLA on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axcella Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $394.00 in company stock.Percentage Held by InsidersOnly 6.50% of the stock of Axcella Health is held by insiders.Percentage Held by Institutions71.05% of the stock of Axcella Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Axcella Health are expected to grow in the coming year, from ($1.39) to ($0.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axcella Health is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axcella Health is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxcella Health has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Axcella Health (NASDAQ:AXLA) StockAxcella Health, Inc. is a biotechnology company. It engages in the research and development of treatment for diseases and improves health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125, for non-alcoholic steatohepatitis. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.Read More Receive AXLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axcella Health and its competitors with MarketBeat's FREE daily newsletter. Email Address AXLA Stock News HeadlinesMarch 19, 2023 | americanbankingnews.comAxcella Health (AXLA) to Release Quarterly Earnings on MondayMarch 19, 2023 | americanbankingnews.comAxcella Health (AXLA) Scheduled to Post Earnings on MondayMarch 22, 2023 | PressReach (Ad)This Stock Has Room To RunAnalysts believe this stock's product demand could rise quickly in the next few years.February 16, 2023 | markets.businessinsider.comNoble Financial Keeps Their Buy Rating on Axcella Health (AXLA)February 16, 2023 | msn.comWhy Is Axcella Health (AXLA) Stock Up 35% Today?February 15, 2023 | finance.yahoo.comAxcella Announces FDA IND Clearance Supporting Regulatory Path to Registration of AXA1125 for Long COVID FatigueFebruary 9, 2023 | finance.yahoo.comAxcella Therapeutics to Participate in the SVB Securities’ 2023 Global Biopharma ConferenceJanuary 25, 2023 | finance.yahoo.comWith lean staff, low cash, Axcella races ahead with Long Covid drugMarch 22, 2023 | PressReach (Ad)This Stock Has Room To RunAnalysts believe this stock's product demand could rise quickly in the next few years.January 24, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Axcella Health (AXLA)January 23, 2023 | marketwatch.comAxcella Health Shares Surge 53% on U.K. Regulator Guidance on AXA1125 for Long Covid FatigueJanuary 23, 2023 | finance.yahoo.comAxcella Announces Regulatory Path to Registration of AXA1125 for Long COVID FatigueDecember 23, 2022 | finance.yahoo.comAxcella Therapeutics Puts Development Of NASH Program Aside, Reduces Workforce By 85%December 15, 2022 | finance.yahoo.comAxcella Announces Program Reprioritization and Corporate RestructuringNovember 11, 2022 | finance.yahoo.comAxcella Health Inc. (AXLA) Loses 47.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerNovember 4, 2022 | markets.businessinsider.comSVB Securities Keeps Their Buy Rating on Axcella Health (AXLA)November 3, 2022 | finance.yahoo.comAxcella to Present at the American Association for the Study of Liver Diseases (AASLD) Annual MeetingNovember 1, 2022 | msn.comRecap: Axcella Health Q3 EarningsNovember 1, 2022 | finance.yahoo.comAxcella Reports Third Quarter Financial Results and Provides Business UpdateOctober 27, 2022 | finance.yahoo.comAxcella Therapeutics to Report Third Quarter 2022 Financial Results on November 1, 2022October 21, 2022 | seekingalpha.comAXLA Axcella Health Inc.October 14, 2022 | finance.yahoo.comAxcella Therapeutics to Participate in the H.C. Wainwright 6th Annual NASH Investor ConferenceOctober 13, 2022 | finance.yahoo.comAxcella Therapeutics Announces $34.2 Million Registered Direct Offering of Common Stock Priced At The Market: Appoints Two New Board MembersOctober 5, 2022 | msn.comLooking Into Axcella Health's Recent Short InterestSeptember 29, 2022 | nasdaq.comAxcella Reports Encouraging Interim Data From EMMPACT Study Of AXA1125September 29, 2022 | seekingalpha.comAxcella adds 20% as mid-stage trial indicates potential of NASH therapySeptember 29, 2022 | finance.yahoo.comAxcella Shares Jump Despite Mixed Bag Data From Mid-Stage NASH TrialSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AXLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axcella Health and its competitors with MarketBeat's FREE daily newsletter. Email Address AXLA Company Calendar Last Earnings11/10/2021Today3/22/2023Next Earnings (Estimated)3/29/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXLA CUSIPN/A CIK1633070 Webwww.axcellahealth.com Phone(857) 320-2200Fax617-441-6243Employees59Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.25 High Stock Price Forecast$8.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+1,153.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-567.25% Return on Assets-147.10% Debt Debt-to-Equity Ratio2.33 Current Ratio1.23 Quick Ratio1.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.56 per share Price / Book0.75Miscellaneous Outstanding Shares73,560,000Free Float68,774,000Market Cap$30.81 million OptionableNot Optionable Beta1.60 Key ExecutivesWilliam R. HinshawPresident, Chief Executive Officer & DirectorTony TramontinChief Scientific Officer, Senior VP-R&DMargaret KozielChief Medical Officer & Senior Vice PresidentPaul FehlnerSecretary, Chief Legal Officer & Senior VPStephen MitchenerChief Business Officer & Senior Vice PresidentKey CompetitorsSolid BiosciencesNASDAQ:SLDBTRACON PharmaceuticalsNASDAQ:TCONAchilles TherapeuticsNASDAQ:ACHLPluriNASDAQ:PLURProtara TherapeuticsNASDAQ:TARAView All CompetitorsInsiders & InstitutionsMargaret KozielSold 679 sharesTotal: $393.82 ($0.58/share)Millennium Management LLCBought 97,359 shares on 2/15/2023Ownership: 0.132%Flagship Pioneering Inc.Bought 10,383,760 shares on 2/14/2023Ownership: 39.766%Geode Capital Management LLCBought 28,364 shares on 2/13/2023Ownership: 0.325%William HinshawSold 16,000 sharesTotal: $24,960.00 ($1.56/share)View All Insider TransactionsView All Institutional Transactions AXLA Stock - Frequently Asked Questions Should I buy or sell Axcella Health stock right now? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axcella Health in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXLA shares. View AXLA analyst ratings or view top-rated stocks. What is Axcella Health's stock price forecast for 2023? 4 equities research analysts have issued 12-month target prices for Axcella Health's shares. Their AXLA share price forecasts range from $2.00 to $8.00. On average, they expect the company's stock price to reach $5.25 in the next twelve months. This suggests a possible upside of 1,153.6% from the stock's current price. View analysts price targets for AXLA or view top-rated stocks among Wall Street analysts. How have AXLA shares performed in 2023? Axcella Health's stock was trading at $0.3275 at the beginning of 2023. Since then, AXLA shares have increased by 27.9% and is now trading at $0.4188. View the best growth stocks for 2023 here. Are investors shorting Axcella Health? Axcella Health saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 1,860,000 shares, an increase of 48.8% from the February 13th total of 1,250,000 shares. Based on an average trading volume of 1,620,000 shares, the short-interest ratio is currently 1.1 days. Currently, 7.0% of the company's shares are sold short. View Axcella Health's Short Interest. When is Axcella Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023. View our AXLA earnings forecast. How were Axcella Health's earnings last quarter? Axcella Health Inc. (NASDAQ:AXLA) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.04. What is Bill Hinshaw's approval rating as Axcella Health's CEO? 5 employees have rated Axcella Health Chief Executive Officer Bill Hinshaw on Glassdoor.com. Bill Hinshaw has an approval rating of 100% among the company's employees. This puts Bill Hinshaw in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 77.0% of employees surveyed would recommend working at Axcella Health to a friend. What other stocks do shareholders of Axcella Health own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axcella Health investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Evofem Biosciences (EVFM), ADMA Biologics (ADMA), Coty (COTY), Energy Transfer (ET), Myovant Sciences (MYOV), NVIDIA (NVDA), Pfizer (PFE) and Moderna (MRNA). When did Axcella Health IPO? (AXLA) raised $76 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 3,600,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and SVB Leerink acted as the underwriters for the IPO. What is Axcella Health's stock symbol? Axcella Health trades on the NASDAQ under the ticker symbol "AXLA." Who are Axcella Health's major shareholders? Axcella Health's stock is owned by many different retail and institutional investors. Top institutional shareholders include Flagship Pioneering Inc. (39.77%), Geode Capital Management LLC (0.33%), Millennium Management LLC (0.13%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David R Epstein, Des Produits Nestle S Societe, Manu Chakravarthy, Margaret Koziel, Paul Fehlner, Robert Crane, Ventures Fund Iv LP Flagship and William Hinshaw. View institutional ownership trends. How do I buy shares of Axcella Health? Shares of AXLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Axcella Health's stock price today? One share of AXLA stock can currently be purchased for approximately $0.42. How much money does Axcella Health make? Axcella Health (NASDAQ:AXLA) has a market capitalization of $30.81 million. The company earns $-64,630,000.00 in net income (profit) each year or ($1.66) on an earnings per share basis. How can I contact Axcella Health? Axcella Health's mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The official website for the company is www.axcellahealth.com. The company can be reached via phone at (857) 320-2200, via email at ir@axcellahealth.com, or via fax at 617-441-6243. This page (NASDAQ:AXLA) was last updated on 3/22/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.